Sugi Predict

Sugi Predict / Compounds / SCHEMBL4586148

SCHEMBL4586148

SCHEMBL4586148

CC(C)c1nc(N)cc(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 6/20 0.41
▸ NOS3 P29474 5/20 0.41
▸ NOS1 P29475 5/20 0.41
▸ HRH4 Q9H3N8 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 3/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1318237 0.84 LMNA (0.37) LMNAALDH1A1
SCHEMBL10399424 0.84 NOS2 (0.48) NOS2NOS3NOS1HRH4MAPT
SCHEMBL31436573 0.83 NOS2 (0.37) NOS2NOS3NOS1KDM4ELMNA
SCHEMBL26598615 0.78 ADORA2A (0.33) NOS2NOS3NOS1LMNAMAPT
SCHEMBL30606159 0.78 ADORA2A (0.33) NOS2NOS3NOS1LMNAMAPT
SCHEMBL8601025 0.76 KMT2A (0.36) NOS2NOS3NOS1KDM4ELMNA
SCHEMBL2717960 0.76 NOS2 (0.57) NOS2NOS3NOS1HRH4ALDH1A1
SCHEMBL2717428 0.76 NOS2 (0.48) NOS2NOS3NOS1HRH4ALDH1A1
SCHEMBL10167708 0.76 NOS3 (0.38) NOS2NOS3NOS1LMNAALDH1A1
SCHEMBL1586144 0.76 LMNA (0.42) KDM4ELMNAMAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 — — WO disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 — — WO disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 — — WO disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
WO-2022240876-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2022-11-17 — — WO disclosed
CN-102516182-A Preparation method for 4-amino-6-alkoxyl pyrimidine compounds YWK CHEMICALS TAICANG CO LTD 2012-06-27 — — CN disclosed
EP-1558609-A4 KINASE INHIBITORS MERCK & CO INC (US) 2008-05-28 — — EP disclosed
EP-1558609-A2 KINASE INHIBITORS Merck & Co., Inc. (US) 2005-08-03 — — EP disclosed
WO-2004041164-A2 KINASE INHIBITORS MERCK & CO., INC. (US) 2004-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 NOS2 3963/4885NOS3 3618/4885NOS1 3956/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 NOS2 3963/4885NOS3 3618/4885NOS1 3956/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 NOS2 3963/4885NOS3 3618/4885NOS1 3956/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 NOS2 3963/4885NOS3 3618/4885NOS1 3956/4885
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP NOS2 3867/4885NOS3 3412/4885NOS1 3437/4885
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B NOS2 4771/4885NOS3 4383/4885NOS1 4418/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 NOS2 3886/4885NOS3 3586/4885NOS1 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.